ScripThe fourth quarter marked a continuation of weak earnings for many major South Korean pharma firms, hurt by factors including the continued impact of a long-running doctors’ protest against medical r
ScripLarge South Korean pharma firms have reported mixed second-quarter earnings amid the ongoing medical care disruption in the country stemming from the prolonged standoff between the government and medi
ScripMajor South Korean pharma firms reported largely mixed results in the fourth quarter amid a range of factors such as license deal-related income, robust sales of in-house developed prescription drugs
ScripSouth Korean pharma firms reported mixed third-quarter results amid a variety of operational factors, with continued solid performances from Hanmi Pharmaceutical Co., Ltd. and Daewoong Pharmaceutic